Treatment of seasonal or year-round allergic rhinitis in adults and children aged 2 yEars and Nose and older. Preventive treatment of allergic rhinitis of medium and severe course is recommended to start 4 weeks before the expected start of the dusting season. As an auxiliary therapeutic agent in the treatment of acute episodes of sinusitis with antibiotics in adults (including the elderly) and children over 12 yEars and Nose of age. Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children older than 12 yEars and Nose. Treatment of nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients aged 18 and over.
Flix 18g Storage
active substance: mometasone furoate;
1 dose contains 51.8 μg of mometasone furoate monohydrate, which is equivalent to 50 μg of mometasone furoate;
Excipients: glycerin, sodium carboxymethylcellulose-microcrystalline cellulose (Avicel RC-591), sodium citrate dihydrate, citric acid monohydrate, benzalkonium chloride solution, polysorbate 80, purified water.
Flix 18g Dosage form
Nasal spray, suspension.
Main physical and chemical properties: viscous homogeneous whitish, odorless suspension.
Flix 18g Pharmacotherapeutic group
Anti-edema and other drugs for topical use in diseases of the nasal cavity. Corticosteroids. ATX code R01A D09.
Mometasone furoate is a synthetic topical corticosteroid that has a pronounced anti-inflammatory effect. The local anti-inflammatory effect of mometasone furoate is manifested at doses that do not cause systemic effects.
The mechanism of anti-inflammatory and anti-allergic action of mometasone furoate is mainly related to its ability to inhibit the release of mediators of allergic reactions. Mometasone furoate significantly reduces the synthesis / release of leukotrienes from the leukocytes of patients suffering from allergic diseases. Mometasone furoate has been shown to be 10 times more active in cell culture than other steroids, including beclomethasone dipropionate, betamethasone, hydrocortisone and dexamethasone, in inhibiting the synthesis / release of IL-1, IL-5, IL-6 and TNFα. It is also a potent inhibitor of the production of Th2 cytokines, IL-4 and IL-5 from human CD4 + T cells. Mometasone furoate is also 6 times more active than beclomethasone dipropionate and betamethasone, inhibiting IL-5 production.
Studies with provocative tests with antigens applied to the nasal mucosa revealed high anti-inflammatory activity of mometasone furoate in the form of a nasal spray in both early and late allergic reactions. This was confirmed by a decrease (compared to placebo) in histamine levels and eosinophil activity, as well as a decrease (compared to baseline) in the number of eosinophils, neutrophils and epithelial cell adhesion proteins.
Treatment of seasonal or perennial allergic rhinitis in adults and children over 2 years of age. Preventive treatment of allergic rhinitis of moderate and severe course is recommended to begin 4 weeks before the expected start of the pollination season.
As an adjunct to the treatment of acute episodes of sinusitis with antibiotics in adults (including the elderly) and children over 12 years of age.
Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age.
Treatment of nasal polyps and related symptoms, including nasal congestion and olfactory loss, in patients over 18 years of age.
Hypersensitivity to the active substance or to any inactive component of the drug.
Interaction with other medicinal products and other forms of interaction
Concomitant therapy with CYP3A inhibitors, including cobicistat-containing drugs, is expected to increase the risk of systemic side effects. Concomitant use should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects – in which case patients should be monitored for systemic corticosteroid side effects.